The first stem cell de-rived skincare product with human bio-active factors to treat anti-ageing is likely to be launched in five metros, including New Delhi, to propagate its efficacy and affordability.
Following the launch of Cutisera, the five-in-one anti-ageing skincare product by Cipla, its developer Stempe-utics, which is based in Bengaluru, has proposed to popularise this product among the dermatologists in Mumbai, Delhi, Bengaluru, Chen-nai and Hyderabad.
The active ingredients in the product have been tested for in-vitro efficacy using human foreskin fibroblast cultures. The product has also been tested for safety and efficacy in pre-clinical models besides a three-month human volunteer study in India. According to B.N. Manohar, managing director, Stempeutics Research Pvt Ltd, the Indian drug regulatory authority has approved the manufacturing and distribution of this product in India.
The company also plans to target other markets and has registered in Malaysia. “We want to export products from Bengaluru to the southeast market, Indonesia, including Sri Lanka. Each country has different requirements. We are planning to conduct studies and get approvals,” he added.
In two to three months, his firm has produced 8,000 bottles. “Our goal is to sell 50,000 vials in a year. We have competition from P&G, L’Oreal and Kaya for a premium Indian market of Rs 600 to Rs 700 crores segment,” he added.
Priced Rs 2,995 for 30 ml bottle, this stem cell derived skincare product is said to suit all skin types of Indians. It is said globally few products are available and two are from USA — Lumina and Reluma — and one from Korea.
